Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
If extra fluids dont improve headaches, assess lifestyle factors like stress and poor sleep, which can contribute to recurring headaches
- Kurt thought there was a 50% chance all GLP-1 compounding would end in the next 6 months (both 503A and 503B) - Did not mention direct communication from the FDA telling them to stop compounding GLP-1s - ProRx felt it was time to stop due to the end of the shortage in March 2025, and did not feel influenced by the April 1 FDA statement - Kurt thinks 503B production of GLP-1s are underreported and much larger than thought - 503As can't take care of the compounded GLP-1 market at their current capacity - We both have concerns about patient access without compounded GLP-1s and worry it will send more patients to the grey market for RUO injections that don't have the same level of sterility and regulation To view or add a comment, sign in Yesterday the FDA proposed removing GLP-1s from the 503B bulk list, and I spoke to Kurt Lunkwitz from ProRx to talk about changes to GLP-1 compounding
Check the current Lilly eligibility page for the exact device and coverage situation
Fat accumulation in the liver or nonalcoholic fatty liver disease (NAFLD) is strongly related with several metabolic disorders, in particular low HDL cholesterol and high triglycerides, present in patients with type 2 diabetes
MEDvidi has licensed healthcare providers in multiple states who are able to prescribe Lexapro or Zoloft online if deemed clinically necessary
It also overlooks individual variability, non-electrophysiologic effects, and the complex pharmacodynamics of newer agents
